Browsing Tag
Nanomi B.V.
3 posts
Lupin (NSE: LUPIN) secures CGT exclusivity for Risperidone LAI, launches first PrecisionSphere injectable in U.S.
Lupin Limited launches Risperidone injectable in the U.S. with 180-day CGT exclusivity, marking its entry into long-acting injectables via PrecisionSphere.
Lupin deepens specialty push with VISUfarma acquisition: Can ophthalmology power its next European chapter?
Lupin acquires VISUfarma to expand into Europe’s ophthalmology market. Find out how this deal could reshape its specialty growth strategy.
Lupin launches first U.S. long-acting injectable from Nanomi—what does it mean for its specialty drug future?
Lupin’s risperidone injectable wins FDA approval with 180-day CGT exclusivity—marking the first major milestone for its Nanomi long-acting injectable platform.